Welcome to chemicalbook!
Chinese English Japanese Germany Korea
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook CAS DataBase List Dabigatran Etexilate Mesylate

Dabigatran Etexilate Mesylate synthesis

5synthesis methods
Dabigatran etexilate, also known as BIBR 1048MS, is a direct thrombin inhibitor. Dabigatran is used to prevent strokes in those with atrial fibrillation not caused by heart valve issues, as well as deep vein thrombosis and pulmonary embolism in persons who have been treated for 5–10 days with parenteral anticoagulant (usually low molecular weight heparin), and to prevent deep vein thrombosis and pulmonary embolism in some circumstances. It appears to be as effective as warfarin in preventing nonhemorrhagic strokes and embolic events in those with atrial fibrillation not due to valve problems.
Synthetic Routes
  • ROUTE 1
  • 202112076874935765.jpg

    Devarasetty, Sitaramaiah; Janni, Ravi; Nunna, Rambabu; Suraparaju, Raghu Ram. An improved process for the preparation of Dabigatran Etexilate mesylate and synthesis of its impurities. Pharma Chemica. Volume 10. Issue 4. Pages 127-148. Journal; Online Computer File. (2018).

  • ROUTE 2
  • 202112078029943392.jpg

    Anon. Novel impurities of intermediates of ethyl 3-{[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}-phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl](2-pyridinyl)-amino}propanoate and its mesylate salt. IP.com Journal. Volume 13. Issue 12B. Pages 1-8. Journal; Patent. (2013).

  • ROUTE 3
  • 202112074788746987.jpg

    Cheng, Qingfang; Wang, Qifa; Lu, Wei; Huang, Fenfen; Qin, Yajuan. Synthesis of dabigatran etexilate mesylate. Zhongguo Xinyao Zazhi. Volume 21. Issue 1. Pages 88-91. Journal. (2012).

  • ROUTE 4
  • 202112070984265145.jpg

    De Zani, Daniele; Ferrari, Massimo; Valentincic, Maurizio. Process of preparing dabigatran etexilate mesylate and its intermediates and novel polymorph of dabigatran etexilate. Assignee Erregierre S.p.A., Italy. IT 1422626. (2016).

202112076874935765.jpg

Devarasetty, Sitaramaiah; Janni, Ravi; Nunna, Rambabu; Suraparaju, Raghu Ram. An improved process for the preparation of Dabigatran Etexilate mesylate and synthesis of its impurities. Pharma Chemica. Volume 10. Issue 4. Pages 127-148. Journal; Online Computer File. (2018).

211915-06-9 Synthesis
Dabigatran etexilate

211915-06-9
404 suppliers
$5.00/50mg

Dabigatran Etexilate Mesylate

872728-81-9
432 suppliers
inquiry

-

Yield:872728-81-9 98%

Reaction Conditions:

in acetone at 26 - 36;Industry scale;

Steps:

1

Ethyl 3 - [(2- { [4-(hexyloxycarbonylarninoimmomemyl)phenylammo]methyl } -1 - methyl- lH-benzimidazole-5-carbonyl)pyridm-2-ylamino]propionate base (52.6 kg) (which has preferably been purified beforehand by recrystallization from ethyl acetate) is placed in an agitator apparatus which has been rendered inert and then 293 kg of acetone is added. The contents of the apparatus are heated to 40° C to 46° C with stirring. After a clear solution has formed, the contents of the apparatus is filtered into a second agitator apparatus through a lens filter and then cooled to 30° C to 36° C. 33 kg of acetone precooled to 0° C to 5° C, 7.9 kg of 99.5% methanesulfonic acid, and for rinsing another 9 kg of acetone are placed in the suspended container of the second apparatus. The contents of the suspended container are added in metered amounts to the solution of ethyl 3-[(2-{[4-(hexyloxycarbonylamino- iminomethyl)phenylamino]methyl} - 1 -methyl- 1 H-benzimidazole-5-carbonyl)pyridin-2- ylamino]propionate base at 26° C to 36° C within 15 to 40 minutes. Then the mixture is stirred for 40 to 60 minutes at 26° C to 33° C. It is then cooled to 17° C to 23° C and stirred for a further 40 to 80 minutes. The crystal suspension is filtered through a filter dryer and washed with a total of 270 L of acetone. The product is dried in vacuum at a maximum of 50° C for at least 4 hours. Yield: 54.5-59.4 kg;90%-98% of theory based on ethyl 3-[(2-{[4-(hexyloxycarbonyl- ammoiminomethyl)phenylamino]methyl} - 1 -methyl- 1 H-benzimidazole-5-carbonyl)- pyridm-2-ylamino]propionate base.

References:

WO2012/44595,2012,A1 Location in patent:Page/Page column 15

Dabigatran Etexilate Mesylate Related Search: